← All trials
NCT05754853
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 6, 2023
- Primary completion
- Oct 31, 2025
- Completion date
- Jan 31, 2027
- First posted
- Mar 6, 2023
- Last posted
- Apr 13, 2023
- Enrollment
- 290
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Miracogen Inc.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Chinese Academy of Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.